- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04966637
Identifying Early Chronic Obstructive Pulmonary Disease (COPD) Using Health Administrative Data
Chronic Obstructive Pulmonary Disease (COPD) affects the airways that causes shortness of breath, cough. COPD gets worse over time, and often leads to emergency department visits, hospital visits, frequent doctor appointments and medications. This means COPD is expensive, and severely impacts patient quality of life. Unfortunately, patients are often not properly diagnosed until their disease is fairly advanced. We know a lot about the health care use of people with COPD once they have been diagnosed, but we do not know much about what happens to them leading up to their diagnosis. Through this project we want to better understand the time period prior to COPD diagnosis, so that we can learn more about what happens to people before they are diagnosed.
This project will use health data to find out if we can identify trends in health care use by individuals newly diagnosed with COPD. We will identify people that have COPD based on health records, and look back to find out about their health care use prior to their diagnosis. We will look at data related to doctors' visits, emergency department visits, hospital stays and medications. We want to use these markers to better understand what happens to people before they are diagnosed, and to find out if we can identify risk factors for a COPD diagnosis. We hope by doing this research we can better identify people at risk for COPD and ensure that they receive treatment early, which may improve their health outcomes.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Objectives
- Identifying a cohort of individuals with a new onset of COPD in the between April 1, 2016 and March 31, 2019.
- To determine factors associated with a new diagnosis of COPD through using traditional mixed-model regression.
- To evaluate whether information collected within administrative data can be used to create a prediction model for a COPD diagnosis.
- To determine whether machine learning methodology improves the prediction of a new COPD diagnosis from administrative data.
Measures:
- The cohort of individuals with COPD in Alberta has already been defined, and this data exists within the Alberta Health Services, Respiratory Health Strategic Clinical Network (RHSCN) dataset. It will be used to further identify individuals with a new diagnosis of COPD within the three year study time period.
In order to conduct this study, a variety of data sets will be used including:
- Inpatient Discharge Abstract Database;
- Practitioner Claims Database;
- Provincial Registry Database;
- Population Health Database and
- Pharmaceutical information Network
Project Hypothesis We anticipate individuals with a diagnosis of COPD in the last three years will have identifiable markers associated with lung disease in the five years prior to their diagnosis. These markers may include: diagnosis of acute respiratory disease (such as pneumonia, bronchitis, upper respiratory infections), increased health care utilization, and the use of medications such as antibiotics.
The project plan will address the specific project goals as follows:
- Identifying a cohort of individuals with a new onset of COPD from April 1, 2016 to March 30, 2019. Through the RHSCN, a cohort of individuals with COPD has been identified of over 200,000 individuals with COPD in Alberta. This cohort will be refined to identify only those individuals that have been diagnosed within the specified time period. This time period was chosen due to data availability. Given our most recent data, we know that approximate 19,000 individuals have been diagnosed with COPD per year, over the last five years. Thus we can approximate that our dataset will include approximately 55,000 individuals with COPD diagnosed in a three year time period.
- Retrospectively review the pattern of health care utilization for individuals with a new diagnosis of COPD in the five years prior to their diagnosis. The health care utilization (ED visits, hospitalization visits, physician visits) for each case in the cohort for the previous five years will be identified.
- Explore the medication use for individuals with COPD for five years prior to their diagnosis. Lastly, the medication use for each case identified in the cohort during the time period five years prior to their diagnosis will be explored. The Pharmaceutical Information Network (PIN) database will be used to identify all medications (both respiratory and non-respiratory) for individuals in the cohort to assess medication use prior to diagnosis.
- Working with the machine learning provider (AltaML) we will additionally conduct a machine learning based analysis to further explore this data set regarding the same variables.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2R3
- University of Alberta
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Must have had at least one visit to a physician with a diagnosis of COPD (by ICD-9(-CM) 491-492, 496) or one hospital separation with a diagnosis of COPD (ICD-10-CA J41-44).
- Incidence criteria included 5 year washout period in which they were not in Alberta, Canada but did not have any diagnosis of COPD
- Individuals that meet this criteria with a new diagnosis in the last 3 years will be included in the cohort, thus individuals with their 'incident' diagnosis of COPD in the last three years will be included (01-APR-2016 to 31-MAR-2017, 01-APR-2017 to 31-MAR-2018; 01-APR-2018 to 31-MAR-2019)
Exclusion Criteria:
- Individuals that were diagnosed with COPD prior to or after the enrollment period.
- Individuals that did not live in Alberta (with access to Alberta health care) during the five year washout period
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Individuals with COPD
This retrospective annual analysis will use the following validated case definition to identify a cohort of individuals with COPD: an individual aged 35 years and older having at least one visit to a physician with a diagnosis of COPD (by ICD-9(-CM) 491-492, 496) or one hospital separation with a diagnosis of COPD (ICD-10-CA J41-44) between April 1, 2016 and March 31, 2019. This is a retrospective descriptive study with administrative data and no intervention will be administered to the cohort |
as this a retrospective descriptive study no intervention will be administered to study participants
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
determine factors associated with a new diagnosis of COPD
Time Frame: each patient's COPD incidence diagnosis date and a COPD incidence diagnosis date (minus 5 years)
|
Health care utilization (physician visits, hospitalizations, emergency department visits, dispensed medication for the cohort of patients five year prior to their diagnosis will be evaluated
|
each patient's COPD incidence diagnosis date and a COPD incidence diagnosis date (minus 5 years)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
prediction model for COPD
Time Frame: each patient's COPD incidence diagnosis date and a COPD incidence diagnosis date (minus 5 years)
|
Health care utilization (physician visits, hospitalizations, emergency department visits, dispensed medication for the cohort of patients five year prior to their diagnosis will be evaluated
|
each patient's COPD incidence diagnosis date and a COPD incidence diagnosis date (minus 5 years)
|
|
machine learning prediction model for COPD
Time Frame: each patient's COPD incidence diagnosis date and a COPD incidence diagnosis date (minus 5 years)
|
Health care utilization (physician visits, hospitalizations, emergency department visits, dispensed medication for the cohort of patients five year prior to their diagnosis will be evaluated using machine learning
|
each patient's COPD incidence diagnosis date and a COPD incidence diagnosis date (minus 5 years)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael Stickland, PhD, University of Alberta
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00097014
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease (COPD
-
Ryme Medical, Inc.Not yet recruitingCOPD | Lung Disease, Chronic Obstructive | COPD Patients | COPD Acute Exacerbation | COPD (Chronic Obstructive Pulmonary Disease) | Lung Disease Airways | COPD Exacerbations
-
University College, LondonUniversity of Cambridge; National Institute for Health Research, United Kingdom and other collaboratorsUnknownChronic Obstructive Pulmonary Disease (COPD).United Kingdom
-
Virginia Commonwealth UniversityFisher and Paykel HealthcareCompletedChronic Obstructive Pulmonary Disease(COPD)United States
-
Reham Mohammed ElmorshedyCompletedChronic Obstructive Pulmonary Disease(COPD)Egypt
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease (COPD).United Kingdom
-
Morair Medtech, LLCRecruitingEmphysema | COPD | Emphysema or COPD | COPD (Chronic Obstructive Pulmonary Disease) | Emphysema, PulmonaryAustria, Germany, Netherlands
-
Medtronic BRCUnknownCOPD | COPD Exacerbation
-
Beaumont HospitalAerogenCompletedChronic Obstructive Pulmonary Disease | COPD | COPD Exacerbation | Copd Exacerbation AcuteIreland
-
Chiesi Farmaceutici S.p.A.CompletedModerate to Severe Chronic Obstructive Pulmonary Disease (COPD)Bulgaria, Germany, Hungary, Poland, Russian Federation, United Kingdom
-
Chiesi Farmaceutici S.p.A.CompletedChronic Obstructive Pulmonary Disease (COPD) | COPDUnited Kingdom
Clinical Trials on COPD cohort
-
China-Japan Friendship HospitalRecruitingChronic Obstructive Pulmonary DiseaseChina
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic Obstructive
-
University of California, San FranciscoNational Heart, Lung, and Blood Institute (NHLBI)RecruitingCOPD (Chronic Obstructive Pulmonary Disease)United States
-
NHS Greater Glasgow and ClydeUniversity of GlasgowUnknownChronic Obstructive Pulmonary DiseaseUnited Kingdom
-
Y Biologics Inc.Novotech (Australia) Pty LimitedActive, not recruitingAdvanced Solid TumorsKorea, Republic of, Thailand, Australia
-
Gelb, Arthur F., M.D.RecruitingEmphysema | COPD, Emphysema, Asthma COPD OverlapUnited States
-
AstraZenecaCompleted
-
Karolinska InstitutetDalarna County Council, SwedenCompleted
-
Institut du Cancer de Montpellier - Val d'AurelleRecruiting